PRQR (proqr.com) שולי הרווח הגולמי

The gross profit margin reflects a trend supported by stable international cold chain supplies of biomaterials. The business relies on a proprietary RNA editing system and partnerships with pharmaceutical behemoths. Meanwhile, compliance with ESG standards necessitates expenditures for chemical waste processing. The current value of 86.20 serves as a baseline indicator of operating profitability, capturing the resilience of the ProQR Therapeutics N.V. (PRQR) production model against market volatility.
פילוחי מדדים פיננסיים ומדדי שוק עבור ProQR Therapeutics NV (PRQR)

The scaling dynamics of the Axiomer platform and the expansion into RNA therapeutics by ProQR Therapeutics (PRQR) are reflected in the gross profit margin, allowing for an assessment of production cost efficiency. This indicator is calculated as the ratio of the difference between revenue and cost of goods sold to total revenue, determining the business's ability to generate profit before operating expenses, which serves as a key criterion of the asset's fundamental stability for investors.